Zheng Quan Ri Bao Wang·2025-07-04 04:45Core Viewpoint - The launch of the innovative weight loss drug, Xin'ermei (generic name: Masitide Injection), by Innovent Biologics marks a significant advancement in obesity treatment, being the world's first GCG/GLP-1 dual receptor agonist approved for long-term weight control in adults with obesity or overweight [1][2]. Group 1: Drug Efficacy and Mechanism - Xin'ermei operates through a dual-target mechanism, enhancing weight loss effects and reducing visceral fat compared to GLP-1 single-target drugs, while also improving metabolic issues such as hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia [1]. - Clinical trials demonstrated significant weight loss efficacy with Masitide at dosages of 4mg and 6mg over 32 and 48 weeks in overweight or obese individuals who struggled with weight control through diet and exercise alone [1]. Group 2: Market Launch and Collaboration - The online launch of Xin'ermei on JD Health provides a new treatment option for overweight and obese patients in China, with expectations for broader clinical applications in areas like fatty liver and adolescent obesity as research progresses [2]. - JD Health's collaboration with Innovent Biologics aims to leverage its full-channel advantages and healthcare service capabilities to facilitate the market expansion of innovative drugs, contributing significantly to the scientific weight loss efforts in China [2]. Group 3: Device Innovation - The newly approved Masitide injection device features significant improvements in convenience and safety, including a needle-free design and a disposable mechanism that minimizes risks during use, along with a pain-free injection experience enabled by innovative X-section technology [2].